BiotechTube
Home/Pipeline/Lead Self-Regulating Immunotherapy

Lead Self-Regulating Immunotherapy

Not Specified

Pre-clinical/Phase 1Active

Key Facts

Indication
Not Specified
Phase
Pre-clinical/Phase 1
Status
Active
Company
NovalGen

About NovalGen

NovalGen is an innovative UK-based biotech advancing a pipeline of multi-specific biologics powered by its novel AutoRegulation platform, designed to enhance safety and efficacy. The company is in the clinical stage, having initiated its first Phase 1 trial for a T-cell engager in 2026 and planning the world's first trial for a self-regulating immunotherapy. With strong academic roots from UCL and strategic partnerships, NovalGen is targeting significant unmet needs across immunology and oncology.

View full company profile

Therapeutic Areas

OncologyAutoimmuneHaematologicalMetabolic

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved